TGFB1 and diabetes mellitus: Thus, in another study targeting DCs in vivo, s.c. microparticle-encapsulated TGF-β was used to enhance diabetes protection of NOD mice (70) and in vitro GM-CSF generated bone marrow-derived DCs (BMDCs), conditioned for 24 h with TGF-β, prolonged islet graft survival in diabetic mouse recipients (71).